Operating Segments (Tables)

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

Segment Reporting for the Quarter Ended March 31, 2024

	Treatment			Services			Segments Total			Corporate (1)			Consolidated Total
Revenue from external customers	$	8,709		$	4,908		$	13,617		$	—		$	13,617
Intercompany revenues		45			16			61			—			—
Gross loss		(52	)		(568	)		(620	)		—			(620	)
Research and development		218			28			246			50			296
Interest income		—			—			—			174			174
Interest expense		(36	)		—			(36	)		(80	)		(116	)
Interest expense-financing fees		—			—			—			(13	)		(13	)
Depreciation and amortization		366			44			410			21			431
Segment loss before income taxes		(1,371	)		(1,388	)		(2,759	)		(1,655	)		(4,414	)
Income tax benefit		(525	)		(431	)		(956	)		—			(956	)
Segment loss		(846	)		(957	)		(1,803	)		(1,655	)		(3,458	)
Expenditures for segment assets		160			84			244			—			244	(2)

Segment Reporting for the Quarter Ended March 31, 2023

	Treatment			Services			Segments Total			Corporate (1)			Consolidated Total
Revenue from external customers	$	9,594		$	10,513		$	20,107		$	—		$	20,107
Intercompany revenues		204			19			223			—			—
Gross profit		1,252			1,757			3,009			—			3,009
Research and development		67			3			70			29			99
Interest income		—			—			—			127			127
Interest expense		(22	)		(1	)		(23	)		(30	)		(53	)
Interest expense-financing fees		—			—			—			(20	)		(20	)
Depreciation and amortization		573			160			733			14			747
Segment income (loss) before income taxes		157			943			1,100			(1,622	)		(522	)
Income tax benefit		(174	)		(30	)		(204	)		—			(204	)
Segment income (loss)		331			973			1,304			(1,622	)		(318	)
Expenditures for segment assets		748			—			748			—			748	(2)

⁽¹⁾ Amounts reflect the activity for corporate headquarters not included in the segment information.

⁽²⁾ Net of financed amount of $44,000 and $50,000 for the three months ended March 31, 2024, and 2023, respectively.